Fatma Akkoc Mustafayev

Dr. Fatma Akkoc Mustafayev

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2023 in Cancer
Verified
Journal Article
Closed access
FMFatma Akkoc Mustafayev
Fatma Akkoc Mustafayev
MSMihir Amitabh Shukla
Mihir Amitabh Shukla
ALAmanda Lanier
Amanda Lanier
DMDenái R. Milton
Denái R. Milton
AGAngelica Gutierrez
Angelica Gutierrez
BABanu K. Arun
Banu K. Arun

19 December 2024 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
KMKhalis Mustafayev
Khalis Mustafayev
MKMert Ahmet Kuskucu
Mert Ahmet Kuskucu
FMFatma Akkoc Mustafayev
Fatma Akkoc Mustafayev
SUSeval Urkmez
Seval Urkmez
BMBilgul Mete
Bilgul Mete
GAGokhan Aygun
Gokhan Aygun
Invasive Candida infections have increased significantly in recent years due to various risk factors, including invasive procedures, vascular catheterization, intra-abdominal surgery, prolonged use of broad-spectrum antibiotics, immunosuppressive medications, hemodialysis, total parenteral nutrition (TPN), and extended intensive care unit (ICU) stays. Candida, one of the top three nosocomial bloodstream infections,

1 June 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SES.N. Esatoglu
S.N. Esatoglu
FMFatma Akkoc Mustafayev
Fatma Akkoc Mustafayev
YOY. Ozguler
Y. Ozguler
FOF. Ozbakir
F. Ozbakir
ONOkan Kadir Nohut
Okan Kadir Nohut
GHG. Hatemi
G. Hatemi
Background Immunogenicity of anti-TNFs has been recognised as an important problem that may cause loss of efficacy and adverse events such as infusion reactions. Anti-TNFs are being increasingly used among patients with Behçet’s syndrome (BS). Objectives We aimed to investigate the prevalence of anti-drug antibodies against infliximab (IFX) in patients with BS together with controls. Methods We collected serum samples from 66 consecutive BS patients (51 M, 15 F and mean age 37±9 years) who were treated with IFX. IFX was used for eye involvement in 43, vascular involvement in 12, nervous system involvement in 8 and arthritis in 2 patients. Additionally, 53 ankylosing spondylitis (AS), 25 Crohn’s disease (CD) and 27 rheumatoid arthritis (RA) patients, and 31 healthy subjects were included as controls. We included patients who had received at least 4 cycles of IFX. Samples were collected just before an infusion, stored at −80o C until analysis, and serum IFX trough levels and anti-IFX antibodies were measured by ELISA at the same time. We used a cut-off value of 1 µg/mL for serum IFX trough level, extrapolating from RA studies. After serum sampling, we continued to follow up patients. Results Anti-IFX antibodies were detected in 4 (6%) BS, 5 (18.5%) RA, 3 (12%) CD, and 1 (%2) AS patient, and in none of the healthy subjects. The mean number of IFX cycles was 19±14 in BS, 21±13 in RA, 19±21 in CD, and 33±18 in AS patients. Allergic reactions had occurred in 9 (14%) BS, 6 (22%) RA, 5 (20%) CD, and 4 (7.5%) AS patients. 3/6 RA patients and 3/5 CD patients who had experienced an allergic reaction had anti-IFX antibodies whereas none of BS and AS patients did. The median serum IFX trough level was significantly lower in patients with anti-IFX antibodies compared to those without antibodies (2.32 (IQR: 0.6–3.6) vs 3.35 (IQR: 1.63–5.6; p=0.019). The serum IFX trough level was lower than the cut off value in 6/13 patients with anti-IFX antibodies and in 25/158 without anti-IFX antibodies (46% vs 16%; p=0.015). We were able to get samples before at least 2 consecutive infusions in 27 BS patients and the presence of anti-IFX antibodies was consistent across the samples in all of these patients. We were able to get samples before the infusion and at week 2 in 5 BS patients. Serum IFX level was below 1 µg/mL before IFX and above 1 µg/mL at week 2 in all of these 5 patients. During a median follow up of 1.5 years, 2/4 BS patients with anti-IFX antibodies had flares. Among the 62 patients without anti-IFX antibodies, 49 are still on IFX and IFX was stopped due to remission in 12 and due to infusion reaction in one patient. Overall, 5 infusion reactions occurred during the follow up (4 without anti-IFX antibodies and 1 with anti-IFX antibodies; 6.5% vs 25%). Conclusions Immunogenicity does not seem to be an important problem in BS patients treated with IFX. The frequency of anti-IFX antibodies was lower than RA and CD patients. This might be related to concomitant immunosuppressive and corticosteroid use among BS patients. The presence of anti-IFX antibodies may not be associated with efficacy loss in BS. However, longer follow-up is needed to make that statement as BS has a relapsing-remitting course. Disclosure of Interest None declared

15 September 2026
Verified
Other
Open access
TSTriparna Sen
Triparna Sen
EGElisa Gobbini
Elisa Gobbini
KMKhalis Mustafayev
Khalis Mustafayev
LSLogan S. Spiegelman
Logan S. Spiegelman
FMFatma Akkoc Mustafayev
Fatma Akkoc Mustafayev
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
Small cell lung cancer (SCLC) is an aggressive malignancy marked by rapid progression, early dissemination, and a pronounced propensity for brain metastases (BM), which develop in up to 80% of patients. SCLC is defined by profound genomic instability, lineage plasticity, and rapid drug resistance. The establishment of BM is promoted by neuronal mimicry, enhanced intercellular adhesion, and dynamic cross-talk with astrocytes and microglia. Emerging therapies targeting delta-like ligand 3 and B7H3 have demonstrated encouraging intracranial activity. Despite these advances, treatment resistance and limited brain drug penetration remain major unmet needs. This review highlights recent advances in SCLC BM biology and precision therapeutic strategies.

16 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
FMFatma Akkoc Mustafayev
Fatma Akkoc Mustafayev
EFElena Fountzilas
Elena Fountzilas
MMMark F. Munsell
Mark F. Munsell
RLRachel M Layman
Rachel M Layman
CYClinton Yam
Clinton Yam
BABanu K. Arun
Banu K. Arun
Background/Objectives: Several trials have highlighted the importance of PARP inhibitors (PARPi) in the treatment of BRCA-associated breast cancers (BC), initiating changes in practice. However, data on the real-life outcomes of PARPi therapy is limited. In this study, we characterized the clinical characteristics and outcomes of patients with advanced BC and germline BRCA pathogenic variants (PVs) who received PARPi therapy. Methods: We conducted a retrospective single-institution cohort study of patients with advanced BC and germline BRCA1/2 PVs treated with PARPi. Outcomes included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Survival was estimated using Kaplan–Meier methods, and prognostic factors were evaluated using Cox regression analysis. Results: Of the 107 patients treated with PARPi, 48 (44.9%) and 59 (55.1%) had BRCA1 and BRCA2 PVs, respectively. Ninety-seven patients (90.7%) had invasive ductal carcinoma and 42 (39.3%) had triple-negative BC. Nineteen (17.8%) patients had de novo metastatic BC. Sixty-two (57.9%) patients received at least one line of systemic therapy before PARPi; 24 (22.4%) patients received prior platinum. ORR was 62.6%, and the median duration of response (DoR) was 7 months (range, 2.1–96.2). The median PFS was 9 months (95% CI, 6.9–10.5) and median OS was 25.8 months (95% CI, 18.7–31.5). In multivariable models for PFS, bone metastases (HR = 2.25; 95% CI, 1.40–3.61; p = 0.0008) and lung metastases (HR = 2.40; 95% CI, 1.45–3.98; p = 0.0007) were independently associated with increased risk of progression or death. In multivariable models for OS, brain metastases (HR = 3.54; 95% CI, 1.59–7.90; p = 0.0020), bone metastases (HR = 2.22; 95% CI, 1.27–3.88; p = 0.0050), and lung metastases (HR = 2.38; 95% CI, 1.38–4.11; p = 0.0018), were independently associated with increased risk of death. Conclusions: The clinical outcomes of our real-world patients are similar to those reported in previous clinical trials. In addition, metastatic site distribution was independently prognostic for survival outcomes and may support baseline risk stratification at the time of PARPi initiation. Further studies of predictive markers of response and resistance, as well as sequencing with platinums and combinations with other targeted agents, are needed to optimize the benefits of PARPi in this patient population.

1 October 2023 in European Journal of Breast Health
Verified
Journal Article
Closed access
FMFatma Akkoc Mustafayev
Fatma Akkoc Mustafayev
DLDiane D. Liu
Diane D. Liu
AGAngelica Gutierrez
Angelica Gutierrez
JLJohn E. Lewis
John E. Lewis
NINuhad K. Ibrahim
Nuhad K. Ibrahim
BABanu K. Arun
Banu K. Arun
Objective: Risk-reducing therapy with selective estrogen receptor (ER) modulators and aromatase inhibitors reduce breast cancer risk. However, the effects are limited to ER-positive breast cancer. Therefore, new agents with improved toxicity profiles that reduce the risk in ER-negative breast cancers are urgently needed. The aim of this prospective, short-term, prevention study was to evaluate the effect of dasatinib, an inhibitor of the tyrosine kinase Src, on biomarkers in normal (but increased risk) breast tissue and serum of women at high risk for a second, contralateral primary breast cancer. Materials and Methods: Women with a history of unilateral stage I, II, or III ER-negative breast cancer, having no active disease, and who completed all adjuvant therapies were eligible. Patients underwent baseline fine-needle aspiration (FNA) of the contralateral breast and serum collection for biomarker analysis and were randomized to receive either no treatment (control) or dasatinib at 40 or 80 mg/day for three months. After three months, serum collection and breast FNA were repeated. Planned biomarker analysis consisted of changes in cytology and Ki-67 on breast FNA, and changes in serum levels of insulin-like growth factor 1 (IGF-1), IGF-binding protein 1, and IGF-binding protein 3. The primary objective was to evaluate changes in Ki-67 and secondary objective included changes in cytology in breast tissue and IGF-related serum biomarkers. Toxicity was also evaluated. Results: Twenty-three patients started their assigned treatments. Compliance during the study was high, with 86.9% (20/23) of patients completing their assigned doses. Dasatinib was well tolerated and no drug-related grade 3 and 4 adverse events were observed. Since only one patient met the adequacy criteria for the paired FNA sample, we could not evaluate Ki-67 level or cytological changes. No significant change in serum biomarkers was observed among the three groups. Conclusion: Dasatinib was well tolerated but did not induce any significant changes in serum biomarkers. The study could not fulfill its primary objective due to an inadequate number of paired FNA samples. Further, larger studies are needed to evaluate the effectiveness of Src inhibitors in breast cancer prevention.